No­vo Nordisk grabs a $486M buy­out op­tion on an an­ti-apoC3 an­ti­body for its car­dio R&D group

A cou­ple of months af­ter re­struc­tur­ing its R&D op­er­a­tions, No­vo Nordisk has whipped up a $486 op­tion deal to buy out Stat­en Biotech­nol­o­gy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland